Since the discovery of the BRCA1 and BRCA2 genes in 1994 and 1995 [1, 2], the homologous recombination (HR) repair pathway for DNA damage has become a focus area for tumorigenesis and cancer therapy. The gene discussed is BRCA1; the disease is cancer.